---
document_datetime: 2023-12-07 13:22:55
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elzonris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: elzonris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.5165594
conversion_datetime: 2025-12-20 14:07:05.912176
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ELZONRIS

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0024               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                         | 06/12/2023                          |                                             | PL                               |           |
| IB/0023              | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 09/08/2023                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                                                                                                                                                                                                                                                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10896 /202212 | Periodic Safety Update EU Single assessment - tagraxofusp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/07/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| S/0020              | 2nd annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/04/2023 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of ELZONRIS should be maintained. |
| N/0022              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/03/2023 |     |                                                                                                                                                                                                                                                                   |
| PSUSA/10896 /202207 | Periodic Safety Update EU Single assessment - tagraxofusp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/02/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| IB/0019/G           | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.1.z - Change in the specification parameters | 19/01/2023 | n/a |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 24/11/2022 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0017             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/09/2022 |            | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10896 /202201 | Periodic Safety Update EU Single assessment - tagraxofusp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/09/2022 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0015           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                    | 13/07/2022 | 14/10/2022 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0009             | Update of section 4.4 and 5.3 of the SmPC to reflect safety information from the final report from study 20255431 (CRL-263114) 'Characterization of fixed choroid plexus samples from primate study MPI- 2231-007 by Immunohistochemistry with DT, CD123, IL-3 and IgG' (MEA002) listed as a category 3 study in the RMP. This is a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions. The updated RMP version 2.2 has also been submitted. | 23/06/2022 | 14/10/2022 | SmPC            | SmPC new text: Choroid plexitis was identified during non-clinical studies (see section 5.3). While not observed in clinical studies, if clinical symptoms or signs suggestive of central nervous system (CNS) damage occur, full clinical and neuro-imaging examination, including fundoscopy and brain magnetic resonance imaging, is recommended. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                             |            |            |                     |                                                                                                                                                                                                                                                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0012              | 1st annual re-assessment                                                                                                                                                                                                                                                                                                                                                  | 22/04/2022 | n/a        |                     | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of ELZONRIS should be maintained. |
| IA/0014/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 08/04/2022 | n/a        |                     |                                                                                                                                                                                                                                                                   |
| PSUSA/10896 /202107 | Periodic Safety Update EU Single assessment - tagraxofusp                                                                                                                                                                                                                                                                                                                 | 10/02/2022 | n/a        |                     | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| IB/0011             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                 | 04/01/2022 | 14/10/2022 | SmPC                |                                                                                                                                                                                                                                                                   |
| IAIN/0010           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                | 17/12/2021 | 14/10/2022 | SmPC, Labelling and |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                  |            |            | PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IB/0005   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                       | 29/10/2021 | n/a        |      |
| IB/0007/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 15/10/2021 | 14/10/2022 | SmPC |
| IB/0004/G | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.II.d.2.z - Change in test procedure for the finished product - Other variation      | 01/10/2021 | n/a        |      |
| IB/0002   | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                 | 17/09/2021 | n/a        |      |
| IB/0006   | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                          | 07/09/2021 | n/a        |      |
| IA/0003   | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                       | 16/07/2021 | n/a        |      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0001/G   | This was an application for a group of variations.   | 02/06/2021   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

| product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of manufacturing sites   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|